Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706526 | 0.93 | MAPK8 (0.46) | MAPK8ADORA3ADORA2AKDM4EHSP90AA1 | |
| SCHEMBL19699593 | 0.85 | ADORA3 (0.37) | MAPK8ADORA3ADORA2AADORA1MAPK9 | |
| SCHEMBL19706551 | 0.83 | MAPK8 (0.63) | MAPK8ADORA3ADORA2AKDM4EHSP90AA1 | |
| SCHEMBL19706534 | 0.82 | MAPK8 (0.42) | MAPK8ADORA3ADORA2AKDM4EHSP90AA1 | |
| SCHEMBL19706716 | 0.79 | MAPK8 (0.71) | MAPK8ADORA3ADORA2AKDM4EHSP90AA1 | |
| SCHEMBL19706537 | 0.79 | MAPK8 (0.42) | MAPK8ADORA3ADORA2AKDM4EHSP90AA1 | |
| SCHEMBL19706533 | 0.79 | MAPK8 (0.42) | MAPK8ADORA3ADORA2AKDM4EHSP90AA1 | |
| SCHEMBL19706529 | 0.79 | MAPK8 (0.42) | MAPK8ADORA3ADORA2AKDM4EHSP90AA1 | |
| SCHEMBL19736359 | 0.78 | CYP1A2 (0.51) | MAPK8ADORA3KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL19699607 | 0.77 | ADORA3 (0.40) | MAPK8ADORA3ADORA2AADORA1MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MAPK8 1686/4885ADORA3 3318/4885ADORA2A 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.